Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07567846 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

A Phase 1 study, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
260
Enrollment target

NCT07567846: Recruiting Phase 1 study, sponsored by Genentech.

NCT07567846 is a Phase 1 study that is actively recruiting participants, run by Genentech. The registered enrollment target is 260 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (333% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07567846, a Phase 1 study, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
260 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Interventions

  • DRUG GDC-1261

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2026-04-29
Est. Completion 2027-12-30
Phase Phase 1
Genentech

332 total trials

What NCT07567846 shows while recruiting

NCT07567846 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (333% higher).

The record links to 0 conditions, and to 1 intervention - of which GDC-1261 is the first listed.

NCT07567846 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07567846 about?

NCT07567846 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer". The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

What is the current status of trial NCT07567846?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2026-04-29. Estimated completion is 2027-12-30.

What interventions are being tested in trial NCT07567846?

The interventions under investigation include: GDC-1261 (DRUG).

Who is sponsoring clinical trial NCT07567846?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07567846's enrollment target sits among peer trials

260 160th of 2000 higher than 1,834 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02283996 · 260 participants · Phase 4

    Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

  • NCT03276793 · 260 participants · NA

    Brain Connectivity in Depression

  • NCT03407469 · 260 participants

    Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

  • NCT03713125 · 260 participants · NA

    Executive Function in Early Childhood

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07567846, the US trial registry maintained by the National Library of Medicine. NCT07567846 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.